View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Feb. 13 (HealthDay News) -- Merck's Zioptan drops (tafluprost ophthalmic solution) have been approved by the U.S. Food and Drug Administration to lower pressure within the eye among people with high blood pressure of the eye (ocular hypertension) or open-angle glaucoma, the most common form of the disease.
Approval was based on five clinical studies involving 905 people, the drug's maker said in a news release. The most common side effects included increased pigmentation of the iris and eyelids, and changes in the thickness and color of the eyelashes.
The product should not be used by children or by pregnant women, Merck warned. It also should be used "with caution" among nursing women and by people with macular edema.
Zioptan should be on pharmacy shelves in March, the Whitehouse Station, N.J., company said.
Medline Plus has more about glaucoma.
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top